Lipfendra: A New Once-Daily Pill for Stubborn Cholesterol

The FDA just approved a cholesterol drug I've been watching for years: Lipfendra, the first pill version of a PCSK9 inhibitor. PCSK9 inhibitors are a class of medication that block a protein in your liver called PCSK9, which normally interferes with your liver's ability to clear LDL cholesterol (the "bad" cholesterol) out of your bloodstream. Until now, every drug in this class came as a shot, either every two weeks or twice a year, and that put off a lot of patients even when their numbers badly needed the extra help beyond a statin. Lipfendra works the same way but as a tablet you take once a day, and it's actually a neat piece of chemistry — it's built from a looped chain of amino acids called a macrocyclic peptide, which is part of why it took about 20 years to turn this mechanism into something you can swallow instead of inject. For patients who've told me flatly they won't do injections, this actually changes what I can offer them.

Key Findings & Takeaways

• What it is: Lipfendra (enlicitide) is the first FDA-approved oral PCSK9 inhibitor, cleared on July 16, 2026 for adults with high cholesterol, including familial hypercholesterolemia — an inherited condition that causes very high LDL from a young age, regardless of diet.
• How it works: Blocking PCSK9 leaves more LDL receptors in place on your liver cells, so your liver can pull more cholesterol out of your blood.
• How well it worked: In the CORALreef Lipids and CORALreef HeFH trials, patients saw their LDL cholesterol drop 56% to 59% more than placebo at 24 weeks, and most reached their target levels.
• How to take it: One tablet a day, on an empty stomach, then wait at least 30 minutes before eating or drinking anything besides water, black coffee, or plain tea.
• How it compares: The other PCSK9 inhibitors on the market require an injection every two weeks (Repatha, Praluent) or twice a year (Leqvio). This is the first one you just swallow.
• Side effects: In the trials, diarrhea showed up in about 7% of patients on Lipfendra versus 2% on placebo, and dizziness in about 9% versus 4%. Both were mild enough that patients stayed on the drug at about the same rate as those on placebo.
• Who it's for: This is an add-on for patients whose LDL stays high despite a statin, or who can't tolerate statins. It's not a replacement for diet, exercise, or a statin when a statin is appropriate.

If you're already on a statin and your LDL still isn't where it needs to be — or you've been putting off treatment because you don't want another needle — this is worth a conversation with your cardiologist. It's not for everyone, but for the patients who've been avoiding injections, it's a real new option.

Reference Source: FDA — FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol

Journal Article: New England Journal of Medicine — A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide